Therapeutic vaccine against DPP4 improves glucose metabolism in mice

Proceedings of the National Academy of Sciences of the United States of America

Volumn 111, Issue 13, 2014, Pages

  Pang, Zhengda ^a   Nakagami, Hironori ^b   Osako, Mariana K ^b   Koriyama, Hiroshi ^b   Nakagami, Futoshi ^a   Tomioka, Hideki ^a   Shimamura, Munehisa ^b   Kurinami, Hitomi ^b   Takami, Yoichi ^a   Morishita, Ryuichi ^a   Rakugi, Hiromi ^a  

^a OSAKA UNIVERSITY   (Japan)

^b OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV ANTIBODY; E1 PEPTIDE; E2 PEPTIDE; E3 PEPTIDE; ENZYME ANTIBODY; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INSULIN; NEUTRALIZING ANTIBODY; PEPTIDE VACCINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; ANTIBODY TITER; ARTICLE; AUTOIMMUNITY; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; GLUCOSE METABOLISM; GLYCEMIC CONTROL; HORMONE BLOOD LEVEL; INSULIN BLOOD LEVEL; INSULIN SENSITIVITY; LIPID DIET; LOW DRUG DOSE; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS; POSTPRANDIAL STATE; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE ACTIVATION; TREATMENT OUTCOME; VACCINATION;

AMINO ACID SEQUENCE; ANIMALS; ANTIGENS; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; DIET, HIGH-FAT; DIPEPTIDYL PEPTIDASE 4; DISEASE MODELS, ANIMAL; GLUCOSE; INSULIN RESISTANCE; LYMPHOCYTE ACTIVATION; MALE; MICE; MICE, INBRED C57BL; PEPTIDES; T-LYMPHOCYTES; TREATMENT OUTCOME; VACCINATION; VACCINES;

EID: 84897560715     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1322009111     Document Type: Article

References (38)

1. Shaw JE, Sicree RA, Zimmet PZ (2010) Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract 87(1):4-14.
2. Drucker DJ,Nauck MA (2006) The incretin system: Glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 368(9548): 1696-1705.
3. Sandhu H, et al. (1999) Glucagon-like peptide 1 increases insulin sensitivity in depancreatized dogs. Diabetes 48(5):1045-1053.
4. Young AA, et al. (1999) Glucose-lowering and insulin-sensitizing actions of exendin-4: Studies in obese diabetic (ob/ob, db/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta). Diabetes 48(5):1026-1034.
5. Zander M, Madsbad S, Madsen JL, Holst JJ (2002) Effect of 6-week course of glucagonlike peptide 1 on glycaemic control, insulin sensitivity, and β-cell function in type 2 diabetes: A parallel-group study. Lancet 359(9309):824-830.
6. Pauly RP, et al. (1996) Investigation of glucose-dependent insulinotropic polypeptide-( 1-42) and glucagon-like peptide-1-(7-36) degradation in vitro by dipeptidyl peptidase IV using matrix-assisted laser desorption/ionization-time of flight mass spectrometry. A novel kinetic approach. J Biol Chem 271(38):23222-23229.
7. Kieffer TJ, McIntosh CH, Pederson RA (1995) Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology 136(8):3585-3596.
8. Baggio LL, Drucker DJ (2007) Biology of incretins: GLP-1 and GIP. Gastroenterology 132(6):2131-2157.
9. Aschner P, et al.; Sitagliptin Study 021 Group (2006) Effect of the dipeptidyl peptidase- 4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 29(12):2632-2637.
10. Deacon CF, Holst JJ (2009) Saxagliptin: A new dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes. Adv Ther 26(5):488-499.
11. Burkey BF, et al. (2005) Acute and chronic effects of the incretin enhancer vildagliptin in insulin-resistant rats. J Pharmacol Exp Ther 315(2):688-695.
12. Drucker DJ (2007) Dipeptidyl peptidase-4 inhibition and the treatment of type 2 diabetes: Preclinical biology and mechanisms of action. Diabetes Care 30(6):1335-1343.
13. Morgan D, et al. (2000) A beta peptide vaccination prevents memory loss in an animal model of Alzheimer?s disease.Nature 408(6815):982-985.
14. Schenk D (2002) Amyloid-β immunotherapy for Alzheimer?s disease: The end of the beginningNat Rev Neurosci 3(10):824-828.
15. Ferrer I, Boada Rovira M, S?nchez Guerra ML, Rey MJ, Costa-Juss? F (2004)europathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer?s disease. Brain Pathol 14(1):11-20.
16. Chen X, et al. (2013) Effectiveness and safety of a therapeutic vaccine against angiotensin II receptor type 1 in hypertensive animals. Hypertension 61(2):408-416.
17. Burnier M (2000) Long-term compliance with antihypertensive therapy: Another facet of chronotherapeutics in hypertension. Blood Press Monit 5(Suppl 1):S31-S34.
18. Ambühl PM, et al. (2007) A vaccine for hypertension based on virus-like particles: Preclinical efficacy and phase I safety and immunogenicity. J Hypertens 25(1):63-72.
19. Winzell MS, Ahrén B (2004) The high-fat diet-fed mouse: A model for studying mechanisms and treatment of impaired glucose tolerance and type 2 diabetes. Diabetes 53(Suppl 3):S215-S219.
20. Wang Q, Brubaker PL (2002) Glucagon-like peptide-1 treatment delays the onset of diabetes in 8 week-old db/db mice. Diabetologia 45(9):1263-1273.
21. Diani AR, et al. (1987) The KKAy mouse: A model for the rapid development of glomerular capillary basement membrane thickening. Blood Vessels 24(6):297-303.
22. Engel M, et al. (2003) The crystal structure of dipeptidyl peptidase IV (CD26) reveals its functional regulation and enzymatic mechanism. Procatl Acad Sci USA 100(9): 5063-5068.
23. Rocca AS, Brubaker PL (1999) Role of the vagus nerve in mediating proximal nutrientinduced glucagon-like peptide-1 secretion. Endocrinology 140(4):1687-1694.
24. Yamazaki K, et al. (2007) Comparison of efficacies of a dipeptidyl peptidase IV inhibitor and alpha-glucosidase inhibitors in oral carbohydrate and meal tolerance tests and the effects of their combination in mice. J Pharmacol Sci 104(1):29-38.
25. Matthews DR, et al. (1985) Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28(7):412-419.
26. Li Y, et al. (2013) The DPP-4 inhibitor MK0626 and exercise protect islet function in early pre-diabetic kkay mice. Peptides 49:91-99.
27. Cribbs DH, et al. (2003) Adjuvant-dependent modulation of Th1 and Th2 responses to immunization with beta-amyloid. Int Immunol 15(4):505-514.
28. Pievani A, et al. (2011) Enhanced killing of human B-cell lymphoma targets by combined use of cytokine-induced killer cell (CIK) cultures and anti-CD20 antibodies. Blood 117(2):510-518.
29. Fu Y. kasawa KM, et al. (1981) Immunohistochemical localization of dipeptidyl aminopeptidase IV in rat kidney, liver, and salivary glands. J Histochem Cytochem 29(3): 337-343.
30. Villanueva-Peñacarrillo ML, Alc?ntara AI, Clemente F, Delgado E, Valverde I (1994) Potent glycogenic effect of GLP-1(7-36)amide in rat skeletal muscle. Diabetologia 37(11):1163-1166.
31. Gedulin BR, et al. (2005) Exenatide (exendin-4) improves insulin sensitivity and betacell mass in insulin-resistant obese fa/fa Zucker rats independent of glycemia and body weight. Endocrinology 146(4):2069-2076.
32. Conarello SL, et al. (2003) Mice lacking dipeptidyl peptidase IV are protected against obesity and insulin resistance. Procatl Acad Sci USA 100(11):6825-6830.
33. Drucker DJ (2006) The biology of incretin hormones. Cell Metab 3(3):153-165.
34. Orgogozo JM, et al. (2003) Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunizationNeurology 61(1):46-54.
35. Nicoll JA, et al. (2003)europathology of human Alzheimer disease after immunization with amyloid-beta peptide: A case reportNat Med 9(4):448-452.
36. Broytman O, Malter JS (2004) Anti-Abeta: The good, the bad, and the unforeseen. Jeurosci Res 75(3):301-306.
37. Nakagami F, et al. (2013) Decrease in blood pressure and regression of cardiovascular complications by angiotensin II vaccine in mice. PLoS ONE 8(3):e60493.
38. Waget A, et al. (2011) Physiological and pharmacological mechanisms through which the DPP-4 inhibitor sitagliptin regulates glycemia in mice. Endocrinology 152(8): 3018-3029.